[144] NewAmsterdam Pharma Company N.V. Warrant SEC Filing

Rhea-AI Filing Summary

NewAmsterdam Pharma Company N.V. insider activity is reported under Rule 144 for ordinary shares. The filer indicates an intended sale of 150,000 ordinary shares through J.P. Morgan Securities LLC with an aggregate market value of $3,780,000, and lists the approximate sale date as 09/09/2025 on NASDAQ. The shares were acquired on 11/22/2022 via an equity compensation exercise-and-sell transaction from the issuer, and payment is listed as cash. The filing also discloses two prior share sales by the same person in the past three months totaling 26,342 shares for gross proceeds of $658,999.39.

Positive

• None.

Negative

• Proposed insider sale of 150,000 shares with an aggregate market value of $3,780,000, which represents a notable disposition of insider-held shares.
• Two recent sales in the past three months totaling 26,342 shares for approximately $658,999.39, indicating ongoing insider selling activity.

Insights

Securities Analyst

TL;DR: Insider plans to sell 150,000 shares (~$3.78M) via broker; prior recent disposals of 26,342 shares noted.

The filing reports a proposed Rule 144 sale executed through a broker, indicating routine disposition of equity compensation proceeds rather than a private transfer. The record shows the shares were acquired by exercise on 11/22/2022 and are to be sold for cash, consistent with typical post‑vesting liquidity events. Two earlier dispositions in the past three months are disclosed, totaling 26,342 shares for roughly $659k, which provides context on recent insider selling activity. Without additional company financials or ownership percentages, this appears to be disclosure of insider liquidation rather than a corporate development.

Corporate Governance Expert

TL;DR: Filing documents compliant Rule 144 notice of proposed sale; signer certifies no undisclosed material nonpublic information.

The notice includes the statutory representation that the seller is unaware of any undisclosed material adverse information about the issuer. The use of a major broker and the listing of acquisition method (equity compensation exercise) align with standard governance and disclosure practices for insider sales. The filing does not state any trading plan adoption date or 10b5‑1 details, and no unusual restrictions or notes about non‑cash consideration are present.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	J.P. Morgan Securities LLC 390 Madison Avenue Floor 6 New York NY 10017	150000	3780000	112628458	09/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	11/22/2022	Exercise and Sell (Equity Compensation)	NewAmsterdam Pharma Company N.V. (issuer)			150000	09/10/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Louise Kooij C/O NewAmsterdam Pharma Compnay N.V. Gooimeer 2-35 Naarden P7 1411 DC	Ordinary Shares	08/25/2025	8269	205547.82
Louise Kooij C/O NewAmsterdam Pharma Compnay N.V. Gooimeer 2-35 Naarden P7 1411 DC	Ordinary Shares	09/03/2025	18073	453451.57

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for NAMSW report?

The filing reports a proposed Rule 144 sale of 150,000 ordinary shares through J.P. Morgan Securities LLC with an aggregate market value of $3,780,000 and an approximate sale date of 09/09/2025.

How were the shares to be sold by the insider acquired?

The shares were acquired on 11/22/2022 via an exercise-and-sell equity compensation transaction from NewAmsterdam Pharma Company N.V.

Has the insider sold shares recently before this proposed sale?

Yes. The filing discloses two sales on 08/25/2025 (8,269 shares, $205,547.82) and 09/03/2025 (18,073 shares, $453,451.57), totaling 26,342 shares and about $658,999.39 in gross proceeds.

Through which broker will the proposed sale be executed?

The sale is planned to be executed through J.P. Morgan Securities LLC (390 Madison Avenue, New York, NY).

Does the filing indicate any non-cash payment for the securities?

No. The table indicates cash as the nature of payment for the proposed sale.